Opigolix

A detailed overview of the drug Opigolix

Opigolix
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Opigolix is a medication that acts as a selective antagonist of the gonadotropin-releasing hormone receptor (GnRH receptor). It is primarily used in the treatment of hormone-dependent conditions such as endometriosis and uterine fibroids.

Mechanism of Action

Opigolix functions by inhibiting the action of gonadotropin-releasing hormone (GnRH), a key hormone in the regulation of the reproductive system. By blocking the GnRH receptor, Opigolix reduces the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This leads to a decrease in the production of estrogen and progesterone by the ovaries, which are hormones involved in the pathophysiology of conditions like endometriosis.

Pharmacokinetics

Opigolix is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is primarily excreted via the kidneys. The drug has a half-life that allows for once or twice daily dosing, depending on the therapeutic regimen.

Clinical Uses

Opigolix is used in the management of:

• Endometriosis: A condition characterized by the presence of endometrial tissue outside the uterus, leading to pain and infertility.
• Uterine fibroids: Non-cancerous growths in the uterus that can cause heavy menstrual bleeding and pelvic pain.

Side Effects

Common side effects of Opigolix include:

• Hot flashes
• Headaches
• Nausea
• Decreased bone mineral density with long-term use

Contraindications

Opigolix is contraindicated in patients with:

• Known hypersensitivity to the drug
• Pregnancy, due to potential harm to the fetus
• Severe liver impairment

Related pages

• Gonadotropin-releasing hormone antagonist
• Endometriosis
• Uterine fibroids

• 

  Opigolix